Dr. Sandhu on Findings with Niraparib in Metastatic Prostate Cancer

Shahneen Sandhu, MD, an associate professor, consultant medical oncologist, and researcher in the Melanoma and Uro-oncology Units at Peter MacCallum Cancer Centre, discusses findings with niraparib (Zejula) in metastatic prostate cancer from the phase 3 MAGNITUDE trial (NCT03748641).

The phase 3 trial assessed the safety and efficacy of niraparib plus abiraterone acetate (Zytiga) and prednisone compared with abiraterone acetate and prednisone plus placebo in patients with metastatic prostate cancer.

Similar to patients with metastatic prostate cancer harboring BRCA1/2 mutations, the addition of niraparib to abiraterone acetate and prednisone elicited efficacy benefits in patients with PALB2, CHEK2, and HDAC2 alterations, Sandhu explains. Notably, these benefits were seen across the study’s end points for these alterations, Sandhu adds.

Though efficacy benefits were observed in patients with ATM and CDK12alterations, they were not evident for all efficacy end points in these subgroups, Sandhu concludes.